Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  crizotinib
Find trials that include:  Any drugs shown
Results 1-19 of 19 for your search:
Start Over
Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E4512, NCI-2014-01507, NCT02201992
ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AP26113-13-301, NCI-2016-00585, NCT02737501
eXalt3: Study Comparing X-396 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: X396-CLI-301, NCI-2016-00877, NCT02767804
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-370, NCI-2016-00707, NCT02574078
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients with Stage III Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RTOG-1306, NCI-2013-00737, NCT01822496
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: ANHL12P1, NCI-2013-02167, COG-ANHL12P1, NCT01979536
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: BRE12-158, NCI-2015-00307, NCT02101385
Pemetrexed Disodium with or without Crizotinib in Treating Patients with Stage IV Non-small Cell Lung Cancer That Has Progressed after Treatment with Crizotinib Alone
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1300, NCI-2014-00685, NCT02134912
Crizotinib following Surgery or Radiation Therapy in Treating Patients with High-Risk Uveal Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-063, NCI-2014-01895, NCI-2015-00689, NCT02223819
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, NCT02465060
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B9991005, NCI-2015-01886, 2015-001879-43, NCT02584634
Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients with Locally Advanced or Metastatic Kidney Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Any age
Trial IDs: S1500, NCI-2015-01707, NCT02761057
A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A8081001, NCI-2009-01775, PROFILE 1001, NCT00585195
Crizotinib and Combination Chemotherapy in Treating Younger Patients with Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 21 years
Trial IDs: ADVL1212, NCI-2012-01968, CDR0000734059, COG-ADVL1212, NCT01606878
Crizotinib and Dasatinib in Treating Younger Patients with Recurrent or Progressive Diffuse Intrinsic Pontine Glioma or High-Grade Glioma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 21
Trial IDs: SJHG12, NCI-2012-01240, NCT01644773
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A4061068, NCI-2014-00350, 2015-001724-31, NCT01999972
Crizotinib and Enzalutamide in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-230, NCI-2014-02361, NCT02207504
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: A8081054, NCI-2015-01364, KEYNOTE 050, CRIZOTINIB, NCT02511184
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Status: Active
Phase: Phase I
Type: Treatment
Age: 1 to 21
Trial IDs: NMTRC012, NCI-2015-01822, NCT02559778
Start Over